The Smart Cancer Patient versus Artificial Intelligence

Panel discussion followed by Q&A by the Audience.

17th-18th June, Stavanger

Speakers:

Emiel Janssen

PhD., Head of quantitative and molecular pathology, Managing director laboratory for molecular biology, Head of research group at Department for Pathology

Dr. Emiel Janssen studied medical biology at the University of Amsterdam. He started his career at the Academic Medical Center in Amsterdam working on neurogenetics. In 2001 he moved to the department of pathology at the Stavanger University Hospital. He received his PhD in 2007 at the University in Bergen and is currently the head of the unit for quantitative and molecular pathology, head of the laboratory for molecular biology and head of the research group from the department of pathology. Since 2015 he is professor in Biomedicine at the University of Stavanger.
The group’s research is devoted to diminishing patient suffering from over –and undertreatment by developing better diagnostics for treatment decision making. The development, validation and implementation of new biomarkers is the main focus of our research. Among the candidate biomarkers microRNA is one group that is currently under investigation; all biomarkers are analysed by using image analysis tools and digital pathology to improve current diagnostics in pathology. Breast cancer, melanomas, gynaecological pre –and cancer and urological cancer are the main diseases which we investigate.

Stavanger University Hospital

Dennis Quan

PhD, Principal

Dr. Dennis Quan is Principal at Instafor LLC, helping companies and entrepreneurs to apply machine learning and enterprise software design practices in the healthcare/life sciences space. He is also an Executive in Residence at Duke University’s Department of Computer Science and a co-founder at Twin Sails Technology Group, having delivered one of the first Meaningful Use-certified electronic health record systems for hospitals that runs completely off the iPad. Spanning a two-decade career in enterprise IT, Dr. Quan held multiple executive leadership roles at IBM, including Engineering VP for IBM’s public cloud infrastructure as well as Director of the IBM Tivoli China Development Laboratory in Beijing and Shanghai. As CTO for IBM High Performance On Demand Solutions, Dr. Quan led IBM’s first cloud computing initiative, culminating in a partnership with Google, the US National Science Foundation, and major universities including MIT, Stanford, UC Berkeley, and Carnegie Mellon in 2007 to support Apache Hadoop-based Big Data research and classroom instruction. He has a number of patents in the area of enterprise transaction processing and has also published dozens of research papers in leading conferences in the fields of Human-Computer Interaction, Bioinformatics, and Semantic Web. Dr. Quan holds a Ph.D. in Computer Science from MIT as well as bachelor’s degrees in Mathematics and Chemistry, also from MIT.  

Substantial experience with all aspects of Enterprise IT. Advised multinational banks, insurance companies, telcos, universities, government agencies, and hospitals on four continents on Hybrid Cloud strategy. Drove due diligence and integration of multiple acquisitions. 4+ years as a business owner and chief architect of mobile hospital electronic health records app. 7+ years’ experience in emerging markets building local relationships and driving technology transfers. Managed 400+ engineer and market management teams doing soup-to-nuts product development, basic research, IP protection, and services delivery. Able to drive maximum productivity out of technology teams across all skill levels and minimize costly architectural/security/scalability blunders leveraging personal experience of having written half a million lines of in-production code on Linux, Windows, Java, and iOS platforms. Able to bridge chasm between healthcare and IT domains due to deep knowledge on clinical, pharmaceutical, diagnostic, billing-related, and regulatory compliance-focused healthcare processes.

Instafor LLC

Kjersti Engan

Professor

University of Stavanger

Thomas Anglero (TBC)

Director of innovation

IBM

Martin Kristensson

Senior Vice President

Martin Kristensson is Senior Vice President, responsible for sales in Europe, leading the EU based sales team. He received his M.Sc. in Biomedical Engineering from the Technical University of Denmark in 2011, specializing in Signal and Model-based Diagnostics, combined with Image Diagnostics and Radiation Physics. In 2014, he became a certified Project Manager.

 

Together with his team, he coordinated the development of Visiopharms clinical products, and the change management processes used to implement the tools in the daily clinical routine across Denmark. In close collaboration with colleagues and customers, he continues to investigate new applications of image analysis within pathology, pursuing new ways of offering standardized high-quality data and diagnosis.

The group’s research is devoted to diminishing patient suffering from over –and undertreatment by developing better diagnostics for treatment decision making. The development, validation and implementation of new biomarkers is the main focus of our research. Among the candidate biomarkers microRNA is one group that is currently under investigation; all biomarkers are analysed by using image analysis tools and digital pathology to improve current diagnostics in pathology. Breast cancer, melanomas, gynaecological pre –and cancer and urological cancer are the main diseases which we investigate.

Visiopharm

Roar Johanssen (TBC)

MD.,Subject Matter Expert Global Markets - Cognitive Solutions Unit Industry Platforms

IBM

Relevant issues/questions:

Demographic changes, number of patient increases, but costs can not continue to increase; how new technology can improve efficiency and quality healthcare - and patient satisfaction?

From biopsy to CT.

From microscope to machine learning.

Patient care from General Practitioner to Hospital to rehabilitation.

Outpatient surgery.

Technology for homebased care and rehabilitation.

Welcome to 37 ºC

The healthtech and lifescience conference and networking oppurtunity of the year.

37 ºC presents an excellent occasion for participating in discussions, product demonstrations and networking, all leading to new business collaborations.

Presentations, panels and discussions will be aimed at providing you with commercial and academic output, stimulate economic and technological development, formation of new alliances for international cooperation, and spark the creation of new technology ventures and new investments

Ticket info

Amounts excl. VAT. Amounts in EUR updated in October 2018.

All tickets Incl. coffee/tea and lunch

Check ticket prices for student:

Don't forget

The event is from monday 17th June to tuesday 18th of June

This allows for anyone that want’s to request and join hikes the weekend 15th-16th June to any of the nearby sights and mountains.

Connect | Explore | grow

See you at 37 °c!